19Apr 2022
Utilization rate and long‐term persistence of combination pharmacotherapy with β3‐agonists and antimuscarinics for overactive bladder refractory to monotherapy in a real‐world setting

Utilization rate and long‐term persistence of combination pharmacotherapy with β3‐agonists and antimuscarinics for overactive bladder refractory to monotherapy in a real‐world setting

The present study aimed to assess real‐world treatment profiles, including utilization rate, time to, and reasons for discontinuation of combination pharmacotherapy with β3‐agonists and antimuscarinics for refractory overactive bladder (OAB) through a retrospective chart review. Records of OAB patients who received β3‐agonists or antimuscarinics at our hospital between 2012 and 2020 were reviewed. The clinical course of patients who progressed to combination therapy was analyzed. Of the 2163 patients receiving β3‐agonists or antimuscarinics, only 84 (3.8%) progressed to combination therapy with both drug classes. While underutilized among OAB patients refractory to monotherapy, combination pharmacotherapy showed a greater persistence rate than published mirabegron or antimuscarinic monotherapy when applied to patients with moderate to severe symptoms. Small sample size at a single institution is the limitation of this study.

  • #urology

Like

Save

Share